ACP
KPTI icon

Acuta Capital Partners’s Karyopharm Therapeutics KPTI Stock Holding History

Acuta Capital Partners’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-39,333
Closed -$11.3M – 36
2019
Q4 		$11.3M Buy
39,333
+23,500
+148% +$5.1M 2.8% 12
2019
Q3 		$2.29M Buy
+15,833
New +$2.15M 1.65% 17

Other funds holding KPTI

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Acuta Capital Partners's KPTI Position: Q1 2020 in Review

Acuta Capital Partners sold out of Karyopharm Therapeutics (KPTI) in Q1 2020, closing a stake of 39,333 shares — an estimated $11.3M sold.

Acuta Capital Partners first reported a position in KPTI in Q3 2019 and held it in 2 quarters. The position peaked at $11.3M in Q4 2019. 136 funds tracked by Wall St. Rank hold KPTI as of Q1 2020.

  • Acuta Capital Partners reported no remaining Karyopharm Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Acuta Capital Partners sold 39,333 Karyopharm Therapeutics shares in Q1 2020, an estimated $11.3M.
  • Acuta Capital Partners first reported a position in Karyopharm Therapeutics in Q3 2019 and held it in 2 quarters.
  • Acuta Capital Partners's Karyopharm Therapeutics position peaked at $11.3M in Q4 2019.
  • 136 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2020.

Based on Acuta Capital Partners's 13F filing for Q1 2020, filed 15 May 2020.